

Advances in the Diagnosis and Prognosis of Breast Cancer's Minor Residual Lesions

Weici Liu*

Abstract


Breast cancer's minor residual lesions post-treatment have posed challenges in accurate diagnosis and prognosis. This article explores recent advancements in the field that have revolutionized the assessment of these

of treatment response and detection of residual cancer cells. AI-driven algorithms analyze imaging and clinical data, aiding in diagnosis and outcome prediction. Genomic profiling identifies genetic alterations influencing residual cancer cell behavior. Predictive models integrate data for recurrence likelihood estimation. While challenges persist, such as standardization and ethical considerations, these innovations hold great promise for personalized medicine and improved patient outcomes.

Keywords:

Introduction

Discussion



*Corresponding author: Weici Liu, Department of Oncology the First School of Clinical Medicine, Jiangsu, China, E-mail: wliu@njmu.edu.cn

Received: 01-Aug-2023, Manuscript No: bccr-23-111666; **Editor assigned:** 02-Aug-2023, Pre QC No: bccr-23-111666 (PQ); **Reviewed:** 16-Aug-2023, QC No: bccr-23-111666; **Revised:** 21-Aug-2023, Manuscript No: bccr-23-111666 (R); **Published:** 28-Aug-2023, DOI: 10.4172/2572-4118.1000206

Citation: Liu W (2023) Advances in the Diagnosis and Prognosis of Breast Cancer's Minor Residual Lesions. Breast Can Curr Res 8: 206.

Copyright: © 2023 Liu W. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

6. A
D.
A/

Future directions

C
A A/
C
A/
E
C
D
A
C
A/
7-11.

Conclusion

B
A/
A
A/
B

Conflict of Interest

Acknowledgment

References

1. Koulis TA, Phan T, Olivotto IA (2015) Hypofractionated whole breast radiotherapy: current perspectives. *Breast Cancer (Dove Med Press)* 7: 363-370.
2. Coles CE, Griffin CL, Kirby AM, Tittley J, Agrawal RK, et al. (2017) Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. *Lancet* 390: 1048-1060.
3. Arps DP, Healy P, Zhao L, Kleer CG, Pang JC (2013) Invasive ductal carcinoma with lobular features: a comparison study to invasive ductal and invasive lobular carcinomas of the breast. *Breast Cancer Res Treat* 138: 719-726.
4. Xiao Y, Ma D, Ruan M, Zhao S, Liu XY, et al. (2017) Mixed invasive ductal and lobular carcinoma has distinct clinical features and predicts worse prognosis when stratified by estrogen receptor status. *Sci Rep* 7: 1-9.
5. Ashrafzadeh S, Ashrafzadeh M, Zarrabi A, Husmandi K, Zabolian A, et al. (2021) Long non-coding RNAs in the doxorubicin resistance of cancer cells. *Cancer Lett* 508:104-114.
6. Ouyang S, Zhou X, Chen Z (2019) LncRNA BCAR4, targeting to miR-665/STAT3 signaling, maintains cancer stem cells stemness and promotes tumorigenicity in colorectal cancer. *Cancer Cell Int* 19:72.
7. Melero I, Castanon E, Alvarez M, Champiat S, Marabelle A (2021) Intratumoural administration and tumour tissue targeting of cancer immunotherapies. *Nat Rev Clin Oncol* 18: 558-576.
8. Brunt AM, Haviland JS, Wheatley DA, Sydenham MA, Alhasso A, et al. (2020) Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial